New classes of HIV inhibitors raise promise for future treatments. HIV experts discuss the most intriguing research.
From CCR5 inhibitors to tweaking the body's immune response, new possibilities exist for HIV treatment, and researchers say they are optimistic that many of these will be effective warriors against HIV disease.
D000071480:APOBEC-3G Deaminase; D019380:Anti-HIV Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D003564:Cytidine Deaminase; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D009700:Nucleoside Deaminases; D011506:Proteins / Q000187:drug effects; D012097:Repressor Proteins
D019380:Anti-HIV Agents; D011506:Proteins; D012097:Repressor Proteins; D009700:Nucleoside Deaminases; D000071480:APOBEC-3G Deaminase; C464924:APOBEC3G protein, human; D003564:Cytidine Deaminase